0NF3.L
Paion AG, a specialty pharmaceutical company, develops and commercializes drugs for hospital-based sedation, anesthesia, and critical care services worldwide. The company's lead product is Remimazolam, an ultra-short-acting intravenous benzodiazepine sedative/anesthetic, which is in clinical development for use in procedural sedation, general anesthesia, and intensive care unit sedation. It is also developing Angiotensin II, a vasoconstrictor indicated for the treatment of refractory hypotension in adults with septic or other distributive shock; and Eravacycline, a novel fluorocycline antibiotic indicated for the treatment of complicated intra-abdominal infections in adults. The company has ...[Read more]
Industry
Medical - Pharmaceuticals
IPO Date
2023-03-10
Stock Exchange
LSE
Ticker
0NF3.L
According to Paion AG’s latest financial reports and current stock price. The company's current PE Ratio is -0.04. This represents a change of -98.52% compared to the average of -2.44 of the last 4 quarters.
The mean historical PE Ratio of Paion AG over the last ten years is -6.53. The current -0.04 PE Ratio has changed -44.87% with respect to the historical average. Over the past ten years (40 quarters), 0NF3.L's PE Ratio was at its highest in in the December 2013 quarter at 4.57. The PE Ratio was at its lowest in in the December 2018 quarter at -10.74.
Average
-6.53
Median
-3.74
Minimum
-54.34
Maximum
26.33
Discovering the peaks and valleys of Paion AG PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 2.04%
Maximum Annual PE Ratio = 26.33
Minimum Annual Increase = -823.73%
Minimum Annual PE Ratio = -54.34
| Year | PE Ratio | Change |
|---|---|---|
| 2022 | -54.34 | 2.04% |
| 2021 | -2.54 | -109.63% |
| 2020 | 26.33 | -453.18% |
| 2019 | -7.46 | 47.43% |
| 2018 | -5.06 | 28.67% |
| 2017 | -3.93 | 84.72% |
| 2016 | -2.13 | 46.19% |
| 2015 | -1.46 | -59.01% |
| 2014 | -3.55 | -68.30% |
| 2013 | -11.20 | -823.73% |
The current PE Ratio of Paion AG (0NF3.L) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-10.18
5-year avg
-8.61
10-year avg
-6.53
Paion AG’s PE Ratio is
| Company | PE Ratio | Market cap |
|---|
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Paion AG using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Paion AG or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Paion AG's PE Ratio?
How is the PE Ratio calculated for Paion AG (0NF3.L)?
What is the highest PE Ratio for Paion AG (0NF3.L)?
What is the 3-year average PE Ratio for Paion AG (0NF3.L)?
What is the 5-year average PE Ratio for Paion AG (0NF3.L)?
How does the current PE Ratio for Paion AG (0NF3.L) compare to its historical average?